[1]Áõ³©,ÁõÏæÔ´*.·Ç´«Í³¿¹Á×Ö¬¿¹ÌåÔÚ²ú¿Æ¿¹Á×Ö¬×ÛºÏÕ÷Õï¶ÏÖеļÛÖµ[J].Öйú¼Æ»®ÉúÓýºÍ¸¾²ú¿Æ,2017,(11):14- 18,23.

µã»÷¸´ÖÆ

·Ç´«Í³¿¹Á×Ö¬¿¹ÌåÔÚ²ú¿Æ¿¹Á×Ö¬×ÛºÏÕ÷Õï¶ÏÖеļÛÖµ

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

£Û1£ÝÖ£Ïþ¾ê£¬µËÏþÀò£¬ÁõÏæÔ´.54Àý¿¹Á×Ö¬×ÛºÏÕ÷»¼ÕßµÄÈÑÉï½á¾Ö£ÛJ£Ý.±±¾©´óѧѧ±¨(ҽѧ°æ)£¬2014£¬46£¨2£©£º323-328. £Û2£ÝÎâÇì¾ü£¬ÖìÑàÁÖ£¬ÌƸ£ÁÖ.¿¹Á×Ö¬×ÛºÏÕ÷100ÀýÁÙ´²ÌØÕ÷·ÖÎö£ÛJ£Ý.Öлª·çʪ²¡Ñ§ÔÓÖ¾£¬2007£¬11£¨11£©£º675-678. £Û3£ÝERKAN D, SALMON J E.The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome £ÛJ£Ý.Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2016, 33(1): 1-7 £Û4£ÝVAN DEN HOOGEN L L, VAN ROON J A, RADSTAKE T R, et al.Delineating the deranged immune system in the antiphospholipid syndrome £ÛJ£Ý.Autoimmunity Reviews, 2016, 15(1): 50-60. £Û5£ÝMEKINIAN A, BOURRIENNE M C, CARBILLON L, et al.Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies£ÛJ£Ý.Seminars in Arthritis and Rheumatism, 2016, 46(2): 232-237. £Û6£ÝSANMARCO M, BOFFA M C.Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome £ÛJ£Ý.Lupus, 2009, 18(10): 920-923. £Û7£ÝSUGI T.Kininogen-dependent antiphosphatidylethanolamine antibodies and autoantibodies to factor XII in patients with recurrent pregnancy losses£ÛJ£Ý.The Journal of Obstetrics and Gynaecology Research, 2013, 39(7): 1223-1229. £Û8£ÝSATO Y, SUGI T, SAKAI R.Autoantibodies to factor XII and Kininogen-Dependent antiphosphatidylethanolamine antibodies in patients with recurrent pregnancy loss augment platelet aggregation£ÛJ£Ý.American Journal of Reproductive Immunology (New York, N.Y.: 1989), 2015, 74(3): 279-289. £Û9£ÝSANMARCO M, ALESSI M C, HARLE J R, et al.Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses £ÛJ£Ý.Thrombosis and Haemostasis, 2001, 85(5): 800-805. £Û10£ÝGRIS J C, QU¦IR¦I I, SANMARCO M, et al.Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss.The N£émes Obstetricians and Haematologists Study¡ª¡ªNOHA£ÛJ£Ý.Thrombosis and Haemostasis, 2000, 84(2): 228-236. £Û11£ÝSUGI T, KATSUNUMA J, IZUMI S, et al.Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses£ÛJ£Ý.Fertility and Sterility, 1999, 71(6): 1060-1065. £Û12£ÝSUGI T, MATSUBAYASHI H, INOMO A, et al.Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss £ÛJ£Ý.The Journal of Obstetrics and Gynaecology Research, 2004, 30(4): 326-332. £Û13£ÝBLANK M, SHOENFELD Y.Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome£ÛJ£Ý.Clinical Reviews in Allergy & Immunology, 2010, 38(2/3): 141-147. £Û14£ÝBERTOLACCINI M L, GOMEZ S, PAREJA J F, et al.Antiphospholipid antibody tests: spreading the net £ÛJ£Ý.Annals of the Rheumatic Diseases, 2005, 64(11): 1639-1643. £Û15£ÝBERTOLACCINI M L, AMENGUAL O, ANDREOLI L, et al.14th international congress on antiphospholipid antibodies task force.report on antiphospholipid syndrome laboratory diagnostics and trends£ÛJ£Ý.Autoimmunity Reviews, 2014, 13(9): 917-930. £Û16£Ý¦nIGON P, PERDAN PIRKMAJER K, TOM¦kIC M, et al.Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes £ÛJ£Ý.Journal of Immunology Research, 2015: 975704. £Û17£ÝBERTOLACCINI M L, ATSUMI T, KOIKE T, et al.Antiprothrombin antibodies detected in two different assay systems.Prevalence and clinical significance in systemic lupus erythematosus £ÛJ£Ý.Thrombosis and Haemostasis, 2005, 93(2): 289-297. £Û18£ÝZIGON P, CUCNIK S, AMBROZIC A, et al.Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value £ÛJ£Ý.Clinical & Developmental Immunology, 2013: 724592. £Û19£ÝZHU Lei, LI Chun, LIU Na, et al.Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients £ÛJ£Ý.Clinical Rheumatology, 2017, 36(2): 401-406. £Û20£ÝAMENGUAL O, FORASTIERO R, SUGIURA-OGASAWARA M, et al.Evaluation of phosphatidylserineª²dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study £ÛJ£Ý.Lupus, 2017, 26(3): 266-276. £Û21£ÝESPOSITO G, TAMBY M C, CHANSEAUD Y, et al.Anti-annexin V antibodies: are they prothrombotic?£ÛJ£Ý.Autoimmunity Reviews, 2005, 4(1): 55-60. £Û22£ÝBECAREVIC M.The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome £ÛJ£Ý.Journal of Thrombosis and Thrombolysis, 2016, 42(4): 552-557. £Û23£ÝIRMAN S, SKARABOT M, MU¦kEVIC I, et al.The use of atomic force microscopy to study the pathologic effects of anti-annexin autoantibodies£ÛJ£Ý.Journal of Autoimmunity, 2011, 36(2): 98-105. £Û24£ÝBIZZARO N, TONUTTI E, VILLALTA D, et al.Prevalence and clinical correlation of antiª²phospholipidª²binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages£ÛJ£Ý.Archives of Pathology & Laboratory Medicine, 2005, 129(1): 61-68. £Û25£ÝARNOLD J, HOLMES Z, PICKERING W, et al.Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage£ÛJ£Ý.British Journal of Haematology, 2001, 113(4): 911-914. £Û26£ÝBECAREVIC M, STOJANOVIC L, IGNJATOVIC S, et al.The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome £ÛJ£Ý.Clinical Rheumatology, 2016, 35(5): 1361-1365. £Û27£ÝZHANG Shulan, WU Ziyan, LI Jing, et al.Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome £ÛJ£Ý.Clinical Rheumatology, 2017, 36(2): 407-412. £Û28£ÝSALLE V, SCHMIDT J, SMAIL A, et al.Antibodies directed against annexin A2 and obstetric morbidity£ÛJ£Ý.Journal of Reproductive Immunology, 2016, 118: 50-53. £Û29£ÝPERICLEOUS C, RUIZ-LIM¦VN P, ROMAY-PENABAD Z, et al.Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of ¦Â2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis £ÛJ£Ý.Rheumatology (Oxford, England), 2015, 54(4): 722-727. £Û30£ÝIOANNOU Y, ROMAY-PENABAD Z, PERICLEOUS C, et al.In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept £ÛJ£Ý.Journal of Thrombosis and Haemostasis : JTH, 2009, 7(5): 833-842. £Û31£ÝAGOSTINIS C, DURIGUTTO P, SBLATTERO D, et al.A non-complement-fixing antibody to ¦Â2 glycoprotein I as a novel therapy for antiphospholipid syndrome£ÛJ£Ý.Blood, 2014, 123(22): 3478-3487. £Û32£ÝDE LAAT B, WU Xiao-xuan, VAN LUMMEL M, et al.Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5£ÛJ£Ý.Blood, 2007, 109(4): 1490-1494. £Û33£ÝDE CRAEMER A S, MUSIAL J, DEVREESE K M.Role of anti-domain 1-¦Â2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome £ÛJ£Ý.Journal of Thrombosis and Haemostasis : JTH, 2016, 14(9): 1779-1787. £Û34£ÝDE LAAT B, PENGO V, PABINGER I, et al.The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study£ÛJ£Ý.Journal of Thrombosis and Haemostasis : JTH, 2009, 7(11): 1767-1773. £Û35£ÝMONTALV¦DO S, EL¦PDIO P S, DA SILVA SARAIVA S, et al.Clinical implications of the detection of antibodies directed against domain 1 of ¦Â2-glycoprotein 1 in thrombotic antiphospholipid syndrome £ÛJ£Ý.Thrombosis Research, 2016, 148: 32-37. £Û36£ÝMARCHETTI T, DE MOERLOOSE P, GRIS J C.Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study£ÛJ£Ý.Journal of Thrombosis and Haemostasis : JTH, 2016, 14(4): 675-684. £Û37£ÝMURTHY V, WILLIS R, ROMAY-PENABAD Z, et al.Value of isolated IgA anti-¦Â2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome£ÛJ£Ý.Arthritis and Rheumatism, 2013, 65(12): 3186-3193. £Û38£ÝRUIZ-GARC¦PA R, SERRANO M, MART¦PNEZ-FLORES J ¦B, et al.Isolated IgA anti- ¦Â2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome£ÛJ£Ý.Journal of Immunology Research, 2014 (2014): 704395. £Û39£ÝLEE R M, BRANCH D W, SILVER R M.Immunoglobulin a anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death £ÛJ£Ý.American Journal of Obstetrics and Gynecology, 2001, 185(3): 748-753. £Û40£ÝYAMADA H, TSUTSUMI A, ICHIKAWA K, et al.IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion£ÛJ£Ý.Arthritis and Rheumatism, 1999, 42(12): 2727-2728.